Synergistic effects of hypertension and aging on cognitive function and Hippocampal expression of genes involved in β-amyloid generation and Alzheimer's disease

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 305, Issue 8, 2013, Pages

  Csiszar, Anna ^a,b,c   Tucsek, Zsuzsanna ^a   Toth, Peter ^a   Sosnowska, Danuta ^a   Gautam, Tripti ^a   Koller, Akos ^b   Deak, Ferenc ^a   Sonntag, William E ^a,c   Ungvari, Zoltan ^a,b,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF PÉCS   (Hungary)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

amyloid; Alzheimer's disease; Dementia; Hypertension; Senescence; Tauopathy; Vascular aging; Vascular cognitive impairment

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANGIOTENSIN II; APOLIPOPROTEIN E; BETA SECRETASE; CASPASE 3; GAMMA SECRETASE; MICROTUBULE ASSOCIATED PROTEIN; MUSCARINIC M1 RECEPTOR; NEUROTRANSMITTER RECEPTOR; SERUM AMYLOID P;

AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; COGNITION; CONTROLLED STUDY; GENE EXPRESSION; HIPPOCAMPUS; HYPERTENSION; MALE; MEMORY DISORDER; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPATIAL MEMORY; TAUOPATHY;

Β-AMYLOID; ALZHEIMER'S DISEASE; DEMENTIA; HYPERTENSION; SENESCENCE; TAUOPATHY; VASCULAR AGING; VASCULAR COGNITIVE IMPAIRMENT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HIPPOCAMPUS; HYPERTENSION; MALE; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; RECEPTOR, MUSCARINIC M1; RNA, MESSENGER; SERUM AMYLOID P-COMPONENT;

EID: 84885593973     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00288.2013     Document Type: Article

References (60)

1. Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, Silva AJ. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 6: 51-58, 2003.
2. Antunes M, Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process 13: 93-110, 2012.
3. Bailey-Downs LC, Mitschelen M, Sosnowska D, Toth P, Pinto JT, Ballabh P, Valcarcel-Ares MN, Farley J, Koller A, Henthorn JC, Bass C, Sonntag WE, Ungvari Z, Csiszar A. Liver-specific knockdown of IGF-1 decreases vascular oxidative stress resistance by impairing the Nrf2-dependent antioxidant response: a novel model of vascular aging. J Gerontol A Biol Sci Med Sci 67: 313-329, 2012.
4. Bevins RA, Besheer J. Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory'. Nat Protoc 1: 1306-1311, 2006.
5. Borg JP, Yang Y, De Taddeo-Borg M, Margolis B, Turner RS. The X11alpha protein slows cellular amyloid precursor protein processing and reduces Abeta40 and Abeta42 secretion. J Biol Chem 273: 14761-14766, 1998.
6. Brickman AM, Reitz C, Luchsinger JA, Manly JJ, Schupf N, Muraskin J, DeCarli C, Brown TR, Mayeux R. Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort. Arch Neurol 67: 564-569, 2010.
7. Cao X, Südhof TC. A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293: 115-120, 2001.
8. Capone C, Faraco G, Park L, Cao X, Davisson RL, Iadecola C. The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. Am J Physiol Heart Circ Physiol 300: H397-H407, 2011.
9. Capone C, Faraco G, Peterson JR, Coleman C, Anrather J, Milner TA, Pickel VM, Davisson RL, Iadecola C. Central cardiovascular circuits contribute to the neurovascular dysfunction in angiotensin II hypertension. J Neurosci 32: 4878-4886, 2012.
10. Carnevale D, Lembo G. 'Alzheimer-like' pathology in a murine model of arterial hypertension. Biochem Soc Trans 39: 939-944, 2011.
11. Carnevale D, Mascio G, Ajmone-Cat MA, D'Andrea I, Cifelli G, Madonna M, Cocozza G, Frati A, Carullo P, Carnevale L, Alleva E, Branchi I, Lembo G, Minghetti L. Role of neuroinflammation in hypertension-induced brain amyloid pathology. Neurobiol Aging 33: 205 e219-e229, 2012.
12. Carnevale D, Mascio G, D'Andrea I, Fardella V, Bell RD, Branchi I, Pallante F, Zlokovic B, Yan SS, Lembo G. Hypertension induces brain beta-amyloid accumulation, cognitive impairment, and memory deterioation through activation of receptor for advanced glycation end products in brain vasculature. Hypertension 60: 188-197, 2012.
13. Case AJ, Li S, Basu U, Tian J, Zimmerman MC. Mitochondriallocalized NADPH oxidase 4 is a source of superoxide in angiotensin II-stimulated neurons. Am J Physiol Heart Circ Physiol 305: H19-H28, 2013.
14. Chen Y, Bodles AM, McPhie DL, Neve RL, Mrak RE, Griffin WS. APP-BP1 inhibits Abeta42 levels by interacting with Presenilin-1. Mol Neurodegener 2: 3, 2007.
15. Diaz-Ruiz C, Wang J, Ksiezak-Reding H, Ho L, Qian X, Humala N, Thomas S, Martinez-Martin P, Pasinetti GM. Role of hypertension in aggravating Abeta neuropathology of AD type and tau-mediated motor impairment. Cardiovasc Psychiatry Neurol 2009: 107286, 2009.
16. Dobarro M, Orejana L, Aguirre N, Ramirez MJ. Propranolol restores cognitive deficits and improves amyloid and Tau pathologies in a senescence-accelerated mouse model. Neuropharmacology 64: 137-144, 2013.
17. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352: 1347-1351, 1998.
18. Fotuhi M, Hachinski V, Whitehouse PJ. Changing perspectives regarding late-life dementia. Nat Rev Neurol 5: 649-658, 2009.
19. Ghosal K, Vogt DL, Liang M, Shen Y, Lamb BT, Pimplikar SW. Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci USA 106: 18367-18372, 2009.
20. Girouard H, Park L, Anrather J, Zhou P, Iadecola C. Angiotensin II attenuates endothelium-dependent responses in the cerebral microcirculation through nox-2-derived radicals. Arterioscler Thromb Vasc Biol 26: 826-832, 2006.
21. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42: 2672-2713, 2011.
22. Guenette S, Chang Y, Hiesberger T, Richardson JA, Eckman CB, Eckman EA, Hammer RE, Herz J. Essential roles for the FE65 amyloid precursor protein-interacting proteins in brain development. EMBO J 25: 420-431, 2006.
23. Guo Z, Qiu C, Viitanen M, Fastbom J, Winblad B, Fratiglioni L. Blood pressure and dementia in persons 75 years old: 3-year follow-up results from the Kungsholmen Project. J Alzheimers Dis 3: 585-591, 2001.
24. Ho A, Liu X, Sudhof TC. Deletion of Mint proteins decreases amyloid production in transgenic mouse models of Alzheimer's disease. J Neurosci 28: 14392-14400, 2008.
25. Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman HT, Haroutunian V. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 72: 1720-1726, 2009.
26. Iadecola C, Park L, Capone C. Threats to the mind: aging, amyloid, and hypertension. Stroke 40: S40-S44, 2009.
27. Israeli-Korn SD, Masarwa M, Schechtman E, Abuful A, Strugatsky R, Avni S, Farrer LA, Friedland RP, Inzelberg R. Hypertension increases the probability of Alzheimer's disease and of mild cognitive impairment in an Arab community in northern Israel. Neuroepidemiology 34: 99-105, 2010.
28. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 29: 594-599, 2009.
29. Kanekiyo T, Liu CC, Shinohara M, Li J, Bu G. LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloidbeta. J Neurosci 32: 16458-16465, 2012.
30. Kazama K, Anrather J, Zhou P, Girouard H, Frys K, Milner TA, Iadecola C. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res 95: 1019-1026, 2004.
31. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, Tschanz JT, Mayer LS, Welsh-Bohmer KA, Breitner JC. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 63: 686-692, 2006.
32. Kolstoe SE, Ridha BH, Bellotti V, Wang N, Robinson CV, Crutch SJ, Keir G, Kukkastenvehmas R, Gallimore JR, Hutchinson WL, Hawkins PN, Wood SP, Rossor MN, Pepys MB. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc Natl Acad Sci USA 106: 7619-7623, 2009.
33. Kuller LH, Lopez OL, Jagust WJ, Becker JT, DeKosky ST, Lyketsos C, Kawas C, Breitner JC, Fitzpatrick A, Dulberg C. Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology 64: 1548-1552, 2005.
34. Lin BF, Ku NO, Zahedi K, Whitehead AS, Mortensen RF. IL-1 and IL-6 mediate increased production and synthesis by hepatocytes of acutephase reactant mouse serum amyloid P-component (SAP). Inflammation 14: 297-313, 1990.
35. Louneva N, Cohen JW, Han LY, Talbot K, Wilson RS, Bennett DA, Trojanowski JQ, Arnold SE. Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease. Am J Pathol 173: 1488-1495, 2008.
36. Lovat LB, O'Brien AA, Armstrong SF, Madhoo S, Bulpitt CJ, Rossor MN, Pepys MB, Hawkins PN. Scintigraphy with 123I-serum amyloid P component in Alzheimer disease. Alzheimer Dis Assoc Disord 12: 208-210, 1998.
37. McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev: CD004034, 2009.
38. Mulder SD, Hack CE, van der Flier WM, Scheltens P, Blankenstein MA, Veerhuis R. Evaluation of intrathecal serum amyloid P (SAP) and C-reactive protein (CRP) synthesis in Alzheimer's disease with the use of index values. J Alzheimers Dis 22: 1073-1079, 2010.
39. Perlmutter LS, Barron E, Myers M, Saperia D, Chui HC. Localization of amyloid P component in human brain: vascular staining patterns and association with Alzheimer's disease lesions. J Comp Neurol 352: 92-105, 1995.
40. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging 21: 57-62, 2000.
41. Potter H, Wefes IM, Nilsson LN. The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiol Aging 22: 923-930, 2001.
42. PROGRESS Collaborative Group. Randomised trial of a perindoprilbased blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033-1041, 2001.
43. Reitz C, Tang MX, Manly J, Mayeux R, Luchsinger JA. Hypertension and the risk of mild cognitive impairment. Arch Neurol 64: 1734-1740, 2007.
44. Saluja I, Paulson H, Gupta A, Turner RS. X11alpha haploinsufficiency enhances Abeta amyloid deposition in Alzheimer's disease transgenic mice. Neurobiol Dis 36: 162-168, 2009.
45. Savage MJ, Iqbal M, Loh T, Trusko SP, Scott R, Siman R. Cathepsin G: localization in human cerebral cortex and generation of amyloidogenic fragments from the beta-amyloid precursor protein. Neuroscience 60: 607-619, 1994.
46. Shrivastava-Ranjan P, Faundez V, Fang G, Rees H, Lah JJ, Levey AI, Kahn RA. Mint3/X11gamma is an ADP-ribosylation factor-dependent adaptor that regulates the traffic of the Alzheimer's Precursor protein from the trans-Golgi network. Mol Biol Cell 19: 51-64, 2008.
47. Skoog I, Gustafson D. Update on hypertension and Alzheimer's disease. Neurol Res 28: 605-611, 2006.
48. Song Z, Cai L, Guo L, Tsukamoto Y, Yutani C, Li XA. Accumulation and expression of serum amyloid P component in human atherosclerotic lesions. Atherosclerosis 211: 90-95, 2010.
49. Sparks DL, Scheff SW, Liu H, Landers TM, Coyne CM, Hunsaker JC, 3rd. Increased incidence of neurofibrillary tangles (NFT) in nondemented individuals with hypertension. J Neurol Sci 131: 162-169, 1995.
50. Toth P, Tucsek Z, Sosnowska D, Gautam T, Mitschelen M, Tarantini S, Deak F, Koller A, Sonntag WE, Csiszar A, Ungvari Z. Age-related autoregutory dysfunction exacerbates cerebromicrovascular injury in mice with angiotensin II induced hypertension. J Cereb Blood Flow Metab. 2013 Aug 14. doi:10.1038/jcbfm.2013.143 [Epub ahead of print].
51. Trenkwalder P. The Study on COgnition and Prognosis in the Elderly (SCOPE)-recent analyses. J Hypertens Suppl 24: S107-S114, 2006.
52. Tsukuda K, Mogi M, Iwanami J, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension 54: 782-787, 2009.
53. Urbanyi Z, Lakics V, Erdo SL. Serum amyloid P component-induced cell death in primary cultures of rat cerebral cortex. Eur J Pharmacol 270: 375-378, 1994.
54. Wagsater D, Johansson D, Fontaine V, Vorkapic E, Backlund A, Razuvaev A, Mayranpaa MI, Hjerpe C, Caidahl K, Hamsten A, Franco-Cereceda A, Wilbertz J, Swedenborg J, Zhou X, Eriksson P. Serine protease inhibitor A3 in atherosclerosis and aneurysm disease. Int J Mol Med 30: 288-294, 2012.
55. Wakisaka Y, Chu Y, Miller JD, Rosenberg GA, Heistad DD. Spontaneous intracerebral hemorrhage during acute and chronic hypertension in mice. J Cereb Blood Flow Metab 30: 56-69, 2010.
56. Wang B, Hu Q, Hearn MG, Shimizu K, Ware CB, Liggitt DH, Jin LW, Cool BH, Storm DR, Martin GM. Isoform-specific knockout of FE65 leads to impaired learning and memory. J Neurosci Res 75: 12-24, 2004.
57. Weyer SW, Klevanski M, Delekate A, Voikar V, Aydin D, Hick M, Filippov M, Drost N, Schaller KL, Saar M, Vogt MA, Gass P, Samanta A, Jaschke A, Korte M, Wolfer DP, Caldwell JH, Muller UC. APP and APLP2 are essential at PNS and CNS synapses for transmission, spatial learning and LTP. EMBO J 30: 2266-2280, 2011.
58. Wharton W, Stein JH, Korcarz C, Sachs J, Olson SR, Zetterberg H, Dowling M, Ye S, Gleason CE, Underbakke G, Jacobson LE, Johnson SC, Sager MA, Asthana S, Carlsson CM. The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial. J Alzheimers Dis 32: 147-156, 2012.
59. Zahedi K, Whitehead AS. Regulation of mouse serum amyloid P gene expression by cytokines in vitro. Biochim Biophys Acta 1176: 162-168, 1993.
60. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12: 723-738, 2011.